查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1922764

日本疼痛管理药物市场规模、份额、趋势及预测（按药物类别、适应症、通路和地区划分，2026-2034年）

Japan Pain Management Drugs Market Size, Share, Trends and Forecast by Drug Class, Indication, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 122 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2025年，日本疼痛管理药物市场规模达43.219亿美元。 IMARC集团预测，到2034年，该市场规模将达到52.72亿美元，2026年至2034年的复合年增长率（CAGR）为2.23%。该市场正经历显着增长，主要驱动因素包括人口老化、药物输送技术的创新以及对非阿片类药物治疗需求的不断增长。此外，严格的监管和医疗体系改革也在持续推动全国范围内的市场扩张和治疗方法的进步。

日本疼痛管理药物市场趋势：

人口老化加剧

日本人口老化是疼痛管理药物产业持续需求的关键驱动因素。骨关节炎、慢性背痛和神经病变疾病等与老龄化相关的健康问题的日益增多，直接影响日本疼痛管理药物市场的成长。报告显示，日本老年人口已达到创纪录的3,625万，占总人口的29.3%。其中，65岁及以上的老年人口中，女性2053万，男性1572万。此外，914万老年人仍在工作，凸显了在连续13年人口下降的情况下，日本面临的持续人口结构挑战。作为世界上预期寿命最高的国家之一，日本很大一部分人口需要长期、可持续的疼痛缓解治疗，这通常涉及非类固醇消炎剂（NSAIDs）、抗忧郁症和老年专用药物的联合治疗方法。老年患者更容易出现药物过敏和副作用。医疗机构正透过优先研发更安全、低剂量的药物配方和完善的监测通讯协定来应对这项挑战。此外，关节重建等与老龄化相关的手术数量增加，也推动了术后止痛药物的需求。随着日本人口结构变化的加深，这一趋势将继续扩大其在日本疼痛管理药物市场各个治疗领域的份额。

药物递送和製剂方面的创新

日本製药公司正积极探索药物递送方式的创新，以改善治疗效果和病患舒适度。随着对慢性疼痛和老年护理的日益关注，製药领域正转向采用经皮贴片、缓释片、外用凝胶和喷雾等先进製剂。这些替代製剂能够更精准地控制剂量，持续缓解疼痛，并减少胃肠道和全身副作用，这对老年患者和长期用药者尤其重要。製剂创新还包括开发复方药物和新型化合物，以有效针对镇痛并降低成瘾风险。例如，2024年11月，Eisai在日本推出了Rosevalamin®注射液25mg（甲钴胺），旨在延缓肌萎缩侧索硬化症（ALS）患者的功能障碍进展并缓解疼痛。该产品于9月获得核准，并在完成一项包含130名患者的III期临床试验后上市。这些进展不仅提高了患者的用药依从性，也有助于拓展跨治疗领域的产品线。随着监管机构支持更安全的替代方案，医疗保健专业人员采用新的剂型，预计创新将在未来几年对日本疼痛管理药物市场的前景产生关键影响。

本报告解答的关键问题

  • 日本疼痛管理药物市场目前发展状况如何？未来几年又将如何发展？
  • 日本的疼痛管理药物市场是如何依药物类别细分的？
  • 日本疼痛管理药物市场依适应症分類的组成是怎样的？
  • 日本疼痛管理药物市场按通路分類的组成是怎样的？
  • 日本疼痛管理药物市场按地区分類的情况如何？
  • 请介绍日本疼痛管理药物市场价值链的各个环节。
  • 日本疼痛管理药物市场的主要驱动因素和挑战是什么？
  • 日本疼痛管理药物市场的结构是怎么样的？主要参与者有哪些？
  • 日本疼痛管理药物市场竞争程度如何？

目录

第一章：序言

第二章：调查范围与调查方法

  • 调查目标
  • 相关利益者
  • 数据来源
  • 市场估值
  • 调查方法

第三章执行摘要

第四章：日本疼痛管理药物市场概况

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争资讯

第五章：日本疼痛管理药物市场概况

  • 过去和当前的市场趋势（2020-2025）
  • 市场预测（2026-2034）

第六章：日本疼痛管理药物市场－依药物类别细分

  • 非类固醇消炎剂（NSAIDs）
  • 麻醉剂
  • 抗惊厥药
  • 抗偏头痛药物
  • 抗忧郁症
  • 阿片类药物
  • 其他的

第七章：日本疼痛管理药物市场－依适应症细分

  • 肌肉骨骼疼痛
  • 手术和创伤性疼痛
  • 癌症疼痛
  • 神经病变疼痛
  • 偏头痛
  • 分娩疼痛
  • 纤维肌痛疼痛
  • 烧伤疼痛
  • 牙齿/脸部疼痛
  • 儿童疼痛
  • 其他的

第八章：日本疼痛管理药物市场－依销售管道细分

  • 医院药房
  • 零售药房
  • 网路药房

第九章：日本疼痛管理药物市场：按地区划分

  • 关东地区
  • 关西、近畿地区
  • 中部地区
  • 九州和冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

第十章：日本疼痛管理药物市场的竞争格局

  • 概述
  • 市场结构
  • 市场公司定位
  • 关键成功策略
  • 竞争对手仪錶板
  • 企业估值象限

第十一章主要企业概况

第十二章：日本疼痛管理药物市场：产业分析

  • 驱动因素、限制因素和机会
  • 波特五力分析
  • 价值链分析

第十三章附录

简介目录
Product Code: SR112026A32458

The Japan pain management drugs market size reached USD 4,321.9 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 5,272.0 Million by 2034 , exhibiting a growth rate (CAGR) of 2.23% during 2026-2034 . The market is experiencing significant growth, driven by an aging population, innovation in drug delivery, and rising demand for non-opioid treatments. Moreover, strict regulations and healthcare reforms continue to shape market expansion and therapeutic advancements nationwide.

JAPAN PAIN MANAGEMENT DRUGS MARKET TRENDS:

Rising Geriatric Population

Japan's aging population is a significant driver of sustained demand in the pain management drugs industry. The increasing number of elderly individuals is directly influencing Japan pain management drugs market growth, as age-related health issues such as osteoarthritis, chronic back pain, and neuropathic conditions become more prevalent. According to the reports, Japan's elderly population reached a record 36.25 million, making up 29.3% of the total population. Women aged 65 or older account for 20.53 million, while men total 15.72 million. Additionally, 9.14 million elderly are employed, reflecting ongoing demographic challenges as the population declines for the 13th consecutive year. With life expectancy among the highest globally, a large segment of the population requires long-term, consistent pain relief therapies. These often include a combination of NSAIDs, antidepressants, and specialized treatments tailored to older adults, who are also more vulnerable to drug sensitivity and side effects. Healthcare providers are adapting by prioritizing safer, lower-dose formulations and monitoring protocols. Additionally, the rising rate of age-related surgeries, such as joint replacements, is fueling demand for post-operative pain medications. As Japan's demographic shift deepens, this trend will continue to increase the Japan pain management drugs market share across therapeutic categories.

To get more information on this market Request Sample

Innovation in Drug Delivery and Formulation

Japanese pharmaceutical companies are actively innovating drug delivery methods to improve treatment outcomes and enhance patient comfort. With a growing focus on chronic pain and elderly care, firms are shifting toward advanced options such as transdermal patches, extended-release tablets, and topical gels or sprays. These alternatives allow for more precise dosing, sustained pain relief, and reduced gastrointestinal or systemic side effects, which are particularly important for older adults and long-term users. Innovation in formulation also includes development of combination drugs and novel compounds that target pain more efficiently while reducing dependency risks. For instance, in November 2024, Eisai Co., Ltd. launched Rozebalamin(R) for Injection 25 mg (mecobalamin) in Japan, to slow functional impairment and address pain in amyotrophic lateral sclerosis (ALS) patients. Approved in September, it follows a Phase III trial with 130 patients. These advancements are not only improving adherence but also expanding product offerings across therapeutic categories. As regulatory bodies support safer alternatives and healthcare professionals adopt newer delivery formats, innovation is expected to play a key role in shaping the Japan pain management drugs market outlook in the coming years.

JAPAN PAIN MANAGEMENT DRUGS MARKET SEGMENTATION:

Drug Class Insights:

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Antimigraine Agents
  • Antidepressants
  • Opioids
  • Others
  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Antimigraine Agents
  • Antidepressants
  • Opioids
  • Others

Indication Insights:

  • Musculoskeletal Pain
  • Surgical and Trauma Pain
  • Cancer Pain
  • Neuropathic Pain
  • Migraine Pain
  • Obstetrical Pain
  • Fibromyalgia Pain
  • Burn Pain
  • Dental/Facial Pain
  • Pediatric Pain
  • Others
  • Musculoskeletal Pain
  • Surgical and Trauma Pain
  • Cancer Pain
  • Neuropathic Pain
  • Migraine Pain
  • Obstetrical Pain
  • Fibromyalgia Pain
  • Burn Pain
  • Dental/Facial Pain
  • Pediatric Pain
  • Others

Distribution Channel Insights:

  • Access the comprehensive market breakdown Request Sample
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • Kanto Region
  • Kansai/Kinki Region
  • Central/Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

  • KEY QUESTIONS ANSWERED IN THIS REPORT
  • How has the Japan pain management drugs market performed so far and how will it perform in the coming years?
  • What is the breakup of the Japan pain management drugs market on the basis of drug class?
  • What is the breakup of the Japan pain management drugs market on the basis of indication?
  • What is the breakup of the Japan pain management drugs market on the basis of distribution channel?
  • What is the breakup of the Japan pain management drugs market on the basis of region?
  • What are the various stages in the value chain of the Japan pain management drugs market?
  • What are the key driving factors and challenges in the Japan pain management drugs market?
  • What is the structure of the Japan pain management drugs market and who are the key players?
  • What is the degree of competition in the Japan pain management drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pain Management Drugs Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Pain Management Drugs Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Pain Management Drugs Market - Breakup by Drug Class

  • 6.1 NSAIDs
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Anesthetics
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Anticonvulsants
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)
  • 6.4 Antimigraine Agents
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2020-2025)
    • 6.4.3 Market Forecast (2026-2034)
  • 6.5 Antidepressants
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2020-2025)
    • 6.5.3 Market Forecast (2026-2034)
  • 6.6 Opioids
    • 6.6.1 Overview
    • 6.6.2 Historical and Current Market Trends (2020-2025)
    • 6.6.3 Market Forecast (2026-2034)
  • 6.7 Others
    • 6.7.1 Historical and Current Market Trends (2020-2025)
    • 6.7.2 Market Forecast (2026-2034)

7 Japan Pain Management Drugs Market - Breakup by Indication

  • 7.1 Musculoskeletal Pain
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Surgical and Trauma Pain
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Cancer Pain
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)
  • 7.4 Neuropathic Pain
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2020-2025)
    • 7.4.3 Market Forecast (2026-2034)
  • 7.5 Migraine Pain
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2020-2025)
    • 7.5.3 Market Forecast (2026-2034)
  • 7.6 Obstetrical Pain
    • 7.6.1 Overview
    • 7.6.2 Historical and Current Market Trends (2020-2025)
    • 7.6.3 Market Forecast (2026-2034)
  • 7.7 Fibromyalgia Pain
    • 7.7.1 Overview
    • 7.7.2 Historical and Current Market Trends (2020-2025)
    • 7.7.3 Market Forecast (2026-2034)
  • 7.8 Burn Pain
    • 7.8.1 Overview
    • 7.8.2 Historical and Current Market Trends (2020-2025)
    • 7.8.3 Market Forecast (2026-2034)
  • 7.9 Dental/Facial Pain
    • 7.9.1 Overview
    • 7.9.2 Historical and Current Market Trends (2020-2025)
    • 7.9.3 Market Forecast (2026-2034)
  • 7.10 Pediatric Pain
    • 7.10.1 Overview
    • 7.10.2 Historical and Current Market Trends (2020-2025)
    • 7.10.3 Market Forecast (2026-2034)
  • 7.11 Others
    • 7.11.1 Historical and Current Market Trends (2020-2025)
    • 7.11.2 Market Forecast (2026-2034)

8 Japan Pain Management Drugs Market - Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Retail Pharmacies
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)
  • 8.3 Online Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2020-2025)
    • 8.3.3 Market Forecast (2026-2034)

9 Japan Pain Management Drugs Market - Breakup by Region

  • 9.1 Kanto Region
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Breakup by Drug Class
    • 9.1.4 Market Breakup by Indication
    • 9.1.5 Market Breakup by Distribution Channel
    • 9.1.6 Key Players
    • 9.1.7 Market Forecast (2026-2034)
  • 9.2 Kansai/Kinki Region
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Breakup by Drug Class
    • 9.2.4 Market Breakup by Indication
    • 9.2.5 Market Breakup by Distribution Channel
    • 9.2.6 Key Players
    • 9.2.7 Market Forecast (2026-2034)
  • 9.3 Central/ Chubu Region
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Breakup by Drug Class
    • 9.3.4 Market Breakup by Indication
    • 9.3.5 Market Breakup by Distribution Channel
    • 9.3.6 Key Players
    • 9.3.7 Market Forecast (2026-2034)
  • 9.4 Kyushu-Okinawa Region
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Breakup by Drug Class
    • 9.4.4 Market Breakup by Indication
    • 9.4.5 Market Breakup by Distribution Channel
    • 9.4.6 Key Players
    • 9.4.7 Market Forecast (2026-2034)
  • 9.5 Tohoku Region
    • 9.5.1 Overview
    • 9.5.2 Historical and Current Market Trends (2020-2025)
    • 9.5.3 Market Breakup by Drug Class
    • 9.5.4 Market Breakup by Indication
    • 9.5.5 Market Breakup by Distribution Channel
    • 9.5.6 Key Players
    • 9.5.7 Market Forecast (2026-2034)
  • 9.6 Chugoku Region
    • 9.6.1 Overview
    • 9.6.2 Historical and Current Market Trends (2020-2025)
    • 9.6.3 Market Breakup by Drug Class
    • 9.6.4 Market Breakup by Indication
    • 9.6.5 Market Breakup by Distribution Channel
    • 9.6.6 Key Players
    • 9.6.7 Market Forecast (2026-2034)
  • 9.7 Hokkaido Region
    • 9.7.1 Overview
    • 9.7.2 Historical and Current Market Trends (2020-2025)
    • 9.7.3 Market Breakup by Drug Class
    • 9.7.4 Market Breakup by Indication
    • 9.7.5 Market Breakup by Distribution Channel
    • 9.7.6 Key Players
    • 9.7.7 Market Forecast (2026-2034)
  • 9.8 Shikoku Region
    • 9.8.1 Overview
    • 9.8.2 Historical and Current Market Trends (2020-2025)
    • 9.8.3 Market Breakup by Drug Class
    • 9.8.4 Market Breakup by Indication
    • 9.8.5 Market Breakup by Distribution Channel
    • 9.8.6 Key Players
    • 9.8.7 Market Forecast (2026-2034)

10 Japan Pain Management Drugs Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Products Offered
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Products Offered
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Products Offered
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Products Offered
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Products Offered
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Pain Management Drugs Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix